Prevention of Dextran Anaphylaxis

Ten Years Experience with Hapten Dextran

H.	Harriet	Hedin
K.-G.	Karl-Gösta	Ljungström

Marma Medical AB, Älvkarleby, and Karolinska Institute, Department of Surgery, Danderyd Hospital, Danderyd, Sweden

Key Words

Dextran-induced anaphylactoid/anaphylactic reactions

IgG antibodies

Dextran-reactive antibodies

Immune complexes

Correspondence to: Dr. Harriet Hedin, PhD, Marma Medical AB, Båtsmansvägen 48, S-814 95 Älvkarleby (Sweden), Tel. +46 26 75205, Fax +46 26 75204

Introduction

Postmarketing Surveillance

Dextran-induced anaphylactoid/anaphylactic reactions (DIAR) were described already in the 1950s. The pathomechanism was explained during the 70s as being either non-immunologic, usually mild anaphylactoid reactions, or mostly severe immunologic immune-complex-mediated anaphylactic reactions [1]. The latter are caused by naturally occurring predominantly IgG class dextran-reactive antibodies (DRA) [2]. No IgE class DRA have been demonstrated. The infusion of clinical dextran into a predisposed patient with a high titer of DRA generates large noxious immune complexes, leading to release of vasoactive mediators that cause the clinical symptoms.

Hapten Inhibition

Since severe DIAR is classified as immune complex anaphylaxis, specific hapten inhibition can be used for prevention. If a monovalent hapten (e.g. dextran 1) is injected first, the combining sites of the specific antibodies are blocked. When polyvalent antigen (e.g. clinical dextran) is subsequently injected, the formation of immune complexes is inhibited.

Hapten inhibition with a monovalent hapten dextran (dextran 1, MW 1,000 D; Promit®) has proven to be an effective prophylactic measure in clinical trials performed from 1978 to 1982 on 130,000 patients [3].

We have evaluated all spontaneous reports to the manufacturer and to the WHO database INTDIS regarding adverse reactions to clinical dextran after preinjection of Promit and to Promit alone during 10 years, 1983-1992. The sales figure for Promit was 5.1 million doses distributed to 15 countries during this period, each dose corresponding to one subsequent exposure to clinical dextran.

Results

The worldwide incidence of severe grade III-V DIAR to clinical dextran after the prophylactic use of hapten inhibition was approximately 1/200,000 doses of Promit. In Sweden, where reporting of severe adverse drug reactions is mandatory, the incidence was approximately

1/70,000. This indicates a 35-fold reduction of the incidence of severe DIAR compared to the use of clinical dextran without Promit (table 1) [4]. Only two fatal reactions were reported, i.e. an incidence of 1/2.5 million doses, indicating a 90-fold reduction. Both reactions occurred in patients with extremely high titers of DRA. Mostly mild, side effects to Promit were reported in approximately 1/100,000 doses. These reactions are not antibody mediated.

Conclusion

The introduction of hapten inhibition with Promit has greatly reduced the risk of serious side effects to dextran, making dextran one of the safest colloids in use.

KARGER

E-Mail karger < a karger.ch

Fax+41 61 306 12 34 <http://www.karger.ch>

© 1997 S.KargerAG, Basel

1018-2438/97/1133-0358 S 12.00/0

This article is also accessible online at: <http://BioIVledNet.com/karger>

Table 1. DIAR in Sweden in 1975-1979 [4] and 1983-1992

Grades of

severity

Characteristic symptoms

DIAR, n

1975-1979 (without dextran 1)

1983-1992 (with dextran 1)

III

IV V

Skin manifestations

(flush, erythema, urticaria) Lumbar pain Mild to moderate hypotension

(blood pressure 40-60 mm Hg depending on

duration) Gastrointestinal disturbances Respiratory distress Severe hypotension, shock

(blood pressure 40-60 mm Hg) Bronchospasm

Cardiac and/or respiratory arrest Fatal reaction

94

1/2,000'

78

44

1/70,000'

Total

300

139

' During 1975-79, 647,756 units of clinical dextrans (Macrodex®/Rheomacrodex®) were sold to hospital clinics in Sweden, corresponding to 0.3 million dextran-treated patients [4]. During 1983-92, 1.2 million doses of dextran 1 were sold, which is assumed to correspond to the same number of patients since dextran 1 is given only before the first infusion of clinical dextran.

References

Hcdin H, Richter W: Pathomechanisms of dex-tran-induced anaphylactoid/anaphylactic reactions in man. Int Arch Allergy Appl Immunol 1982;68:122-126.

Kraft D, Hedin H, Richter W, Schemer O, Rum-pold H, Devey ME: Immunoglobulin class and subclass distribution of dextran-reactive antibodies in human reactors and non reactors to clinical dextran. *Allergy* 1982;37:481-489. Ljungström K-G, Renck H, Hedin H, Richter W, Wiholm B-E: Hapten inhibition and dextran anaphylaxis. *Anaesthesia* 1988;43:729-732. Ljungström K-G, Renck H, Strandberg K, Hedin H, Richter W, Widerlöv E: Adverse reactions to dextran in Sweden 1970-1979. *Acta ChirScand* 1983;149:253-262.

Prevention of Dextran Anaphylaxis
Int Arch Allergy Immunol 1997;113:358-359
359
International Archives of
Allergy and Immunology